Literature DB >> 28436456

Synthesis and anti-obesity effects in vivo of Crotadihydrofuran C as a novel PPARγ antagonist from Crotalaria albida.

Qin-Hu Sun1,2, Yu Zhang3, Gui-Xin Chou1,2.   

Abstract

Crotadihydrofuran C (CC) from the herbs of Crotalaria albida is able to inhibit adipocyte differentiation and lipid accumulation. However, the effects of CC on obesity and metabolic disorders have not yet been elucidated. In our study, the first enantioselective synthesis of the 2-isopropenyl dihydrofuran isoflavone skeleton (CC) is described. The convenient and efficient synthetic protocols developed skilfully solve the problems of the ortho-para directing group and Suzuki coupling reaction using a boronic acid pinacol ester that was more stable and easy to obtain. Furthermore, CC treatment of high-fat diet (HFD)-fed obese mice remarkably reduced their body weight, fat mass, and lipid level as well as improved insulin resistance and non-alcoholic fatty liver disease (NAFLD). A TR-FRET assay showed that CC was specifically bound to PPARγ LBD, which was further confirmed by the molecular docking study. These results suggest that CC could be a useful and potential natural product for treating metabolic diseases, including obesity, hyperlipidemia insulin resistance and NAFLD, without toxic side-effects.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28436456      PMCID: PMC5402262          DOI: 10.1038/srep46735

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  38 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

2.  Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.

Authors:  Yong-Xu Wang; Chih-Hao Lee; Sambath Tiep; Ruth T Yu; Jungyeob Ham; Heonjoong Kang; Ronald M Evans
Journal:  Cell       Date:  2003-04-18       Impact factor: 41.582

3.  Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.

Authors:  Ryosuke Nakano; Eiji Kurosaki; Shigeru Yoshida; Masanori Yokono; Akiyoshi Shimaya; Tatsuya Maruyama; Masayuki Shibasaki
Journal:  Biochem Pharmacol       Date:  2006-04-07       Impact factor: 5.858

Review 4.  The obesity epidemic: current and future pharmacological treatments.

Authors:  Karl G Hofbauer; Janet R Nicholson; Olivier Boss
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

5.  Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.

Authors:  T Yamauchi; H Waki; J Kamon; K Murakami; K Motojima; K Komeda; H Miki; N Kubota; Y Terauchi; A Tsuchida; N Tsuboyama-Kasaoka; N Yamauchi; T Ide; W Hori; S Kato; M Fukayama; Y Akanuma; O Ezaki; A Itai; R Nagai; S Kimura; K Tobe; H Kagechika; K Shudo; T Kadowaki
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.

Authors:  J J Plattner; A K Fung; J A Parks; R J Pariza; S R Crowley; A G Pernet; P R Bunnell; P W Dodge
Journal:  J Med Chem       Date:  1984-08       Impact factor: 7.446

7.  7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.

Authors:  Viktor Rempel; Nicole Volz; Sonja Hinz; Tadeusz Karcz; Irene Meliciani; Martin Nieger; Wolfgang Wenzel; Stefan Bräse; Christa E Müller
Journal:  J Med Chem       Date:  2012-09-11       Impact factor: 7.446

8.  Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor.

Authors:  T E D'Ambra; K G Estep; M R Bell; M A Eissenstat; K A Josef; S J Ward; D A Haycock; E R Baizman; F M Casiano; N C Beglin
Journal:  J Med Chem       Date:  1992-01       Impact factor: 7.446

Review 9.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

Review 10.  Obesity and nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  Nutr Rev       Date:  2007-06       Impact factor: 7.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.